Reducing the dose of inhaled corticosteroids (ICS) under therapy with montelukast in stable asthma: effects on lung function and inflammation Source: Eur Respir J 2001; 18: Suppl. 33, 261s Year: 2001
Monitoring of inflammatory changes in patients with bronchial asthma before and after oral corticosteroid treatment Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II Year: 2008
Decreasing dose protocol for omalizumab treatment in oral corticosteroid allergic asthma patients Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011
Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD Source: Eur Respir J 2003; 22: Suppl. 45, 50s Year: 2003
Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD Source: Eur Respir J, 55 (5) 1902119; 10.1183/13993003.02119-2019 Year: 2020
Concomitant use of low-dose inhaled corticosteroids and a long-acting bronchodilatator visavi doubling the dose of inhaled corticosterod in asthma patients Source: Eur Respir J 2001; 18: Suppl. 33, 98s Year: 2001
Immunomodulatory treatment of severe persistent asthma with interferon-αcon-1 (IFN-αcon-1). Effect on the clinical course of oral corticosteroid dose and eosinophil numbers Source: Annual Congress 2003 - Modulation of bronchial hyperreactivity and immune response in the airways Year: 2003
Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids Source: Eur Respir J 2001; 17: 337-342 Year: 2001
Effect of switching from high-dose inhaled corticosteroid (ICS) to low-dose ICS plus an inhaled long-acting β2 -agonist on asthma control, airway inflammation and remodeling, and gene expression in airway epithelial cells Source: Eur Respir J 2003; 22: Suppl. 45, 35s Year: 2003
Cytokines concentrations in induced sputum of mild COPD patients. Correlation to clinical response to inhaled corticosteroids Source: Eur Respir J 2002; 20: Suppl. 38, 309s Year: 2002
Integrating high dose inhaled corticosteroids into oral corticosteroids stewardship Source: Eur Respir J, 55 (1) 1902193; 10.1183/13993003.02193-2019 Year: 2020
Effects of treatment with N-acetylcysteine or inhaled corticosteroids on inflammatory mediators in COPD-patients Source: Eur Respir J 2003; 22: Suppl. 45, 5s Year: 2003
The effects of nebulised bronchodilators and corticosteroids treatment compared with inhaled drug therapy for moderate COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 290s Year: 2004
An economic evaluation of adding inhaled corticosteroids to systemic corticosteroids for treating acute asthma exacerbations Source: International Congress 2019 – Severe acute asthma and troublesome wheezing Year: 2019
Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness Source: Eur Respir J 2006; 27: 1144-1151 Year: 2006
Comparison of the effectiveness of azithromycin and budesonide versus theophylline and budesonide in the suppression of pro-inflammatory cytokines in patients with COPD Source: Virtual Congress 2020 – Intercellular communication in tissue remodelling of chronic lung diseases Year: 2020
Comparative effectiveness of two different doses of inhaled corticosteroid in triple therapy on exacerbations in patients with severe COPD: a real-world study Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19 Year: 2021
Outcome of COPD exacerbations treated with and without oral steroids in relation to airway and systemic inflammation Source: Eur Respir J 2005; 26: Suppl. 49, 283s Year: 2005
Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment Source: Eur Respir J 2006; 27: 964-971 Year: 2006
Oral steroid-sparing effect of high-dose inhaled corticosteroids in asthma Source: Eur Respir J, 55 (1) 1901147; 10.1183/13993003.01147-2019 Year: 2020